Neurocrine Biosciences | NBIX - 운영 비용





운영 비용 변화 날짜
AbbVie USD 10.52B 258M 2026-09
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 11.69B 6.9B 2026-06
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Cytokinetics USD 207.8M 7.22M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Exelixis USD 390.27M 10M 2026-09
Gilead Sciences USD 13.04B 9.09B 2026-09
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Incyte USD 5.64B 4.67B 2026-09
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Pfizer USD 85.19B 4.91B 2026-06
Prothena USD 19.7M 5.6M 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Repligen USD 185.01M 2.01M 2026-09
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09